Four courses will be organised, in three different events as follows:
- November 2020: Pharmacotherapy in Older People - Online
- December 2020: All About Clinical Trials - Online
- 2021: EuroCVP
Reduction of cardiovascular disease burden by pharmacotherapy is a multistep approach, which requires:
- the identification of new potential drugs;
- testing new potential pharmacological compounds in a trial setting;
- regulatory approval;
- implementation of therapies in clinical practice.
Older patients with cardiovascular disease are often shown to be undertreated. Among others, the main reasons are polypharmacotherapy and thus fear for side effects and sparse evidence from trials in this subgroup due to limited enrolment. Therefore, the older subgroup of patients with CV disease represents the ideal population who may benefit from strategies leading to implement the optimised use of pharmacotherapy.
The 2020 Educational Programme aims to provide a deep insight into the long journey which brings pharmacological compounds from bench to bedside, i.e. from trial design for testing new drugs (generation and critical appraisal of evidence) to implementation of daily use of pharmacological treatments, of science and patient care.
To achieve this, the programme is composed of two complementary programmes:
- All About Clinical Trials (AACT)
- Pharmacotherapy in Older People (POP)
The specific aim of the AACT course is to improve competency and confidence in:
- Designing and planning successful clinical trials;
- Evaluating and following the correct processes and regulatory procedures (GCP certificate included);
- Effectively analysing and interpreting trial data through highly interactive workshops.
The specific aim of the POP course is to improve competence and confidence to deliver better, personalised therapy of older people, which in turn will have a positive impact on implementing the use of services and pharmacotherapy and thus patient outcomes.
Who should attend
Both POP and AACT courses are dedicated to healthcare professionals with clinical/research interest in any field of cardiovascular medicine, e.g. atrial fibrillation, heart failure, hypertension, peripheral vascular and cerebrovascular disease, prevention, general cardiology, coronary artery disease, dyslipidaemia, diabetes.
- More specifically, the AACT courses are aimed towards clinical cardiologists and clinical pharmacologists with experience in translational and clinical research in cardiovascular drug therapy. Students or confirmed physicians, who need to improve their knowledge and clinical skills in trial management and interpretation
- More specifically, POP courses are dedicated to physicians dealing with hospital admissions, ward and outpatient consultations
Prof. Heinz Drexel, Austria, Chairperson
Prof. Alexander Niessner, Austria, Chairperson-Elect
Prof. Sven Wassmann, Germany
Prof. Gianluigi Savarese, Sweden
Prof. Juan Tamargo, Spain
Prof. Juan Carlos Kaski, UK
Certification in Good Clinical Practice
Each workshop participant is certified in Good Clinical Practice (GCP) after the course.
GCP is an international ethical and scientific quality standard for the design, conduct, and recording and reporting of clinical trials that involve the participation of human subjects. Anyone managing or conducting research in the National Health Service should be aware of Good Clinical Practice and evidence of GCP training is mandatory for gaining Host Site Approval for a Clinical Trial of an Investigational Medicinal Product (CTIMP).
The course provides a review of the fundamentals of Good Clinical Practice. The training is based on the International Conference on Harmonisation GCP guidelines but also introduces The Medicines for Human Use (Clinical Trials) Regulations and Amendment Regulations 2006, which have transposed the EU Clinical Trials Directive. All latest additions are included. The course gives an overview of aspects applicable to all research.
100% of participants would recommend the course to their peers!
“The course allowed me not only to gain a deeper insight into the complex process of organising clinical trials, but it also offered an opportunity to discuss specific methodological pitfalls and interpret the results in cooperation with professionals who represent the highest level of expertise in the field. I highly recommend the course both to experienced investigators and to young researchers, since apart from the conventional aspects of clinical trials methodology; it also presented a novel approach to run the research efficiently and successfully.” Aleksandra Gąsecka, Poland